AbbVie Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Robert Michael
Chief executive officer
US$32.5m
Total compensation
| CEO salary percentage | 5.23% |
| CEO tenure | 2yrs |
| CEO ownership | 0.01% |
| Management average tenure | 2.3yrs |
| Board average tenure | 8.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$4b |
| Dec 31 2025 | US$33m | US$2m | US$4b |
| Sep 30 2025 | n/a | n/a | US$2b |
| Jun 30 2025 | n/a | n/a | US$4b |
| Mar 31 2025 | n/a | n/a | US$4b |
| Dec 31 2024 | US$18m | US$2m | US$4b |
| Sep 30 2024 | n/a | n/a | US$5b |
| Jun 30 2024 | n/a | n/a | US$5b |
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$14m | US$1m | US$5b |
| Sep 30 2023 | n/a | n/a | US$6b |
| Jun 30 2023 | n/a | n/a | US$9b |
| Mar 31 2023 | n/a | n/a | US$8b |
| Dec 31 2022 | US$10m | US$1m | US$12b |
| Sep 30 2022 | n/a | n/a | US$13b |
| Jun 30 2022 | n/a | n/a | US$13b |
| Mar 31 2022 | n/a | n/a | US$12b |
| Dec 31 2021 | US$12m | US$1m | US$11b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$7b |
| Mar 31 2021 | n/a | n/a | US$5b |
| Dec 31 2020 | US$13m | US$1m | US$5b |
| Sep 30 2020 | n/a | n/a | US$7b |
| Jun 30 2020 | n/a | n/a | US$7b |
| Mar 31 2020 | n/a | n/a | US$8b |
| Dec 31 2019 | US$9m | US$907k | US$8b |
Compensation vs Market: Robert's total compensation ($USD32.53M) is above average for companies of similar size in the TH market ($USD210.37K).
Compensation vs Earnings: Robert's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Robert Michael (56 yo)
Mr. Robert A. Michael, C.P.A., served as Chief Operating Officer at AbbVie Inc. since June 29, 2023 until July 01, 2024 and served as its President since June 23, 2022 until July 01, 2024 also serves as it...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 2yrs | US$32.53m | 0.010% THB 1.5b | |
| Executive VP & CFO | 4.1yrs | US$12.35m | 0.0022% THB 323.5m | |
| Executive VP & COO | 2yrs | US$10.79m | 0.012% THB 1.7b | |
| Executive VP of Research & Development and Chief Scientific Officer | 2yrs | US$9.91m | 0.0031% THB 462.4m | |
| Executive VP & Chief Commercial Officer | no data | US$15.44m | 0.0048% THB 706.2m | |
| Senior VP & Chief Information Officer | less than a year | no data | no data | |
| Senior Vice President of Investor Relations | no data | no data | no data | |
| Executive VP | 3.8yrs | no data | 0.00026% THB 38.4m | |
| Executive VP & Chief Human Resources Officer | 1.5yrs | no data | 0.00045% THB 66.5m | |
| Senior VP & President of Oncology | 2.8yrs | no data | no data | |
| Executive VP and Chief Business & Strategy Officer | 3.5yrs | no data | 0.0042% THB 621.9m | |
| Senior Vice President of Corporate Affairs | 2.5yrs | no data | no data |
Experienced Management: ABBV19's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 2yrs | US$32.53m | 0.010% THB 1.5b | |
| Lead Independent Director | 13.5yrs | US$432.88k | 0.00065% THB 96.0m | |
| Independent Director | 6.2yrs | US$397.88k | 0.0071% THB 1.0b | |
| Independent Director | 1.2yrs | US$328.71k | 0.00017% THB 25.1m | |
| Independent Director | 13.5yrs | US$383.44k | 0.0010% THB 149.2m | |
| Independent Director | 13.5yrs | US$382.88k | no data | |
| Independent Director | 13.5yrs | US$402.88k | 0.00011% THB 16.3m | |
| Independent Director | 9.2yrs | US$407.88k | 0% THB 0 | |
| Independent Director | 10.5yrs | US$397.88k | no data | |
| Independent Director | 8.2yrs | US$372.88k | no data | |
| Independent Director | 2.8yrs | US$359.51k | 0% THB 0 | |
| Independent Director | 2.8yrs | US$372.88k | 0% THB 0 |
Experienced Board: ABBV19's board of directors are considered experienced (8.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/02 13:03 |
| End of Day Share Price | 2026/07/02 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AbbVie Inc. is covered by 51 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Luisa Hector | Berenberg |